According to a recent Kaiser Family Foundation poll, roughly 6% of U.S. adults are currently taking GLP-1 for weight loss, and the effects are impressive. A 2022 study found that people who received weekly semaglutide injections lost an average of about 15 pounds after three months.

Reuters reported in April 2025 that WeightWatchers' stock, which traded as high as $100 in 2018, lost most of its value last year as the company faced revenue declines, liquidity concerns, and celebrity shareholder Oprah Winfrey's decision to exit its board.

The company, which has shaped how millions eat and exercise, is trying to reduce its debt as it expands its telehealth business.